Nuwellis, Inc. (NUWE)

Nuwellis, Inc.'s stock price has experienced significant volatility and a substantial decline over the past six months (July 2025 - January 2026). The share price saw a dramatic decrease of 96.55% from January 2, 2025, to December 31, 2025, and an 86.18% decline over the last six months. Key events include a 1-for-35 reverse stock split on June 28, 2024. In July 2025, the company's stock market value increased by nearly $5 million following a patent acceptance, and FDA designations and promising results boosted investor confidence, leading to a 143.8% increase in stock price on July 16, 2025. On September 18, 2025, Nuwellis announced the issuance of a new U.S. Patent (No. 12,415,021) reinforcing its Vivian™ Pediatric Device. On November 12, 2025, Nuwellis reported its Third Quarter 2025 financial results, reporting $0.56 earnings per share, exceeding analyst estimates, but revenue was $2.22 million, below analyst expectations. On December 4, 2025, the company announced continued clinician-driven growth in pediatric care with a leading hospital in the Northeast U.S. The stock has been affected by continued selling pressure, broader market weakness, low liquidity during holiday trading sessions, and negative technical momentum.

Specific information regarding the demand seasonality for Nuwellis, Inc.'s products and services is not readily available. The available information on seasonality pertains to the historical stock price performance, indicating that June has the highest probability of a positive stock return, while September has the lowest.

Nuwellis, Inc. is a medical device company focused on developing, manufacturing, and commercializing medical devices for ultrafiltration therapy. The company's primary products are the Aquadex FlexFlow and Aquadex SmartFlow systems, designed to remove excess fluid from patients suffering from fluid overload, particularly those with hypervolemia or conditions like acute decompensated heart failure and cardiorenal syndrome, who have not responded to traditional medical management, including diuretics. The Aquadex FlexFlow system includes a console, a disposable blood set, and a catheter.

Nuwellis, Inc. is headquartered in Eden Prairie, Minnesota, United States. The company sells its products to hospitals and clinics through its direct salesforce within the United States. Internationally, Nuwellis distributes its products through independent specialty distributors in various markets, including Austria, Belarus, Brazil, Colombia, the Czech Republic, Germany, Greece, Hong Kong, India, Indonesia, Israel, Italy, Panama, Romania, Singapore, Slovakia, Spain, Switzerland, Thailand, the United Arab Emirates, and the United Kingdom.

Nuwellis's brand reputation over the past year has likely been influenced by a mix of positive developments and challenging financial performance. The significant decline in its stock price could negatively impact its overall market perception. However, the company has also had positive news that could bolster its reputation within the medical community, including a patent acceptance and positive FDA designations in July 2025, clinical success with 92% survival in children with acute kidney injury, a new U.S. patent in September 2025 for its Vivian™ Pediatric Device, and news in December 2025 about clinician-driven growth in pediatric care. On the negative side, a voluntary recall of specific lots of blood circuit units in the fourth quarter of 2024 could have temporarily impacted its reputation.

The ownership structure of Nuwellis (NUWE) stock is a mix of institutional, insider, and retail investors. Approximately 4.39% of the company's stock is owned by institutional investors. Insiders hold a significant portion, with approximately 66.31% of the stock. Retail investors and public companies own the remaining shares, around 29.29%. Major institutional owners include DRW Securities, LLC, Sabby Management, Llc, UBS Group AG, Citigroup Inc, Tower Research Capital LLC (TRC), SBI Securities Co., Ltd., Bank Of America Corp /de/, Bigger Capital Funds, LP, UBS Financial Services, Inc., The Vanguard Group, Inc., Geode Capital Management, L.L.C., and Virtu Financial LLC. Prominent individual and insider owners include John L. Erb (CEO), Mark Harvey, Geoffrey Brooke, Ki Yong Choi, Talu Ventures Pty Ltd, CM Capital, Gbs Venture Partners Pty Ltd, Straus Asset Management LLC, David A. Rosa, and Donal Odwyer. John Erb is noted as owning 66.31% of the company's shares as an insider.